Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 6/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265130 | 1.00 | MMP2 (0.42) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL5988909 | 0.98 | MMP2 (0.40) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12654802 | 0.98 | MMP2 (0.40) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL5988923 | 0.94 | MMP2 (0.36) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12147599 | 0.94 | MMP2 (0.36) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL890063 | 0.90 | AAK1 (0.32) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL890115 | 0.90 | AAK1 (0.32) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12402478 | 0.90 | AAK1 (0.32) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL10072223 | 0.86 | MMP2 (0.40) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL204610 | 0.85 | MMP2 (0.44) | MMP2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8101567-B2 | Heteroaryl-containing tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8030307-B2 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2009070689-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2008019289-A2 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | MMP2 1409/4885CA12 4380/4885CA1 4836/4885 |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, PRSS1, CTSC | MMP2 251/4885CA12 2686/4885CA1 1711/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MMP2 2627/4885CA12 4401/4885CA1 4852/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MMP2 19/4885CA12 3198/4885CA1 2294/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MMP2 2627/4885CA12 4401/4885CA1 4852/4885 |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | PRSS1, CTSC, SPINT2 | MMP2 191/4885CA12 2641/4885CA1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.